Table 1:
Patient Characteristics, dose levels and clinical efficacy.
| Patients (n=8) N (%) |
|
|---|---|
| Median age in years (IQR) | 70 (11.5 ) |
| Gender | |
| Male | 3 (37.5%) |
| Female | 5 (62.5%) |
| Race | |
| African American (AA) | 5 (62.5%) |
| non-AA | 3 (37.5%) |
| ECOG PS=1 | 8 (100%) |
| Smoking status | |
| Never | 3 (37.5%) |
| Active/Former | 5 (62.5%) |
| Histology | |
| Adenocarcinoma | 7 (87.5%) |
| SQCLC | 1 (12.5%) |
| Type of mutations (all with adenocarcinoma) | |
| EGFR | 1 (12.5%) |
| KRAS | 2 (25%) |
| Median lines of prior Treatment (IQR) | 2.5 (2.5) |
| Median follow-up in months (IQR) | 15.4 (10.5) |
| Escalating doses | |
| 15 mg/m2 | 3 (37.5%) |
| 30 mg/m2 | 3 (37.5%) |
| 45 mg/m2 | 2 (25%) |
| Median Treatment cycles (IQR) | 2 (1) |
| Clinical efficacy | |
| Partial Response (PR) | 1 (12.5%) |
| Stable disease (Stable) | 2 (25%) |
| Progression (PD) | 5 (62.5%) |
| Clinical efficacy based on dose levels | |
| 15 mg/m2 | 3 (100%) PD |
| 30 mg/m2 | 1 (33%) PR, 2 (67%) PD |
| 45 mg/m2 | 2 (100%) Stable |